Abstract
Purpose
To investigate the effects of transjugular intrahepatic portosystemic shunt (TIPS) creation using Fluency versus Viatorr stent-grafts on the long-term clinical outcomes.
Materials and Methods
This was a single-center retrospective study from January 2010 to October 2021 in 213 patients receiving TIPS with Fluency (Fluency group, n = 154) versus Viatorr (Viatorr group, n = 59) stent-grafts. Inclusion criteria were: age > 18 years old and TIPS creation for variceal hemorrhage. Exclusion criteria were: age > 80 years old, concomitant chronic heart or lung disease, active tuberculosis or human immunodeficiency virus infection, extrahepatic malignancy, alcohol dependence, TIPS created outside of our hospital, without any follow-up data, or decline to participate. The primary outcome was primary patency rate and its associated risk factors.
Results
The 5-year cumulative primary patency rate was significantly higher in Viatorr group than in Fluency group (89.0% vs. 19.6%, p < 0.001), whereas the 5-year cumulative transplant-free survival rate (62.3% vs. 62.2%, p = 0.636) was comparable between two groups. Cox-regression models revealed that group (hazard ratio [HR]4.029, 95% confidence interval [CI] 1.486–10.927, p = 0.006), use of bare stents (HR 3.307, 95% CI 1.903–5.747, p < 0.001), and baseline portal vein thrombosis (HR 0.248, 95% CI 0.149–0.412, p < 0.001) were significantly associated with shunt patency. Incidences of adverse events were not significantly different between two groups (p > 0.05).
Conclusions
TIPS creation using Viatorr stent-grafts is superior to using Fluency stent-grafts in terms of higher long-term primary patency rate but similar transplant-free survival rate.
This is a preview of subscription content, access via your institution.




Abbreviations
- TIPS:
-
Transjugular intrahepatic portosystemic shunt
- ePTFE:
-
Expanded polytetrafluoroethylene
- HR:
-
Hazard ratio
- CI:
-
Confidence interval
- HE:
-
Hepatic encephalopathy
- CT:
-
Computed tomography
- PVT:
-
Portal vein thrombosis
- PTA:
-
Percutaneous angioplasty
- CTP:
-
Child–Turcotte–Pugh
- MELD:
-
Model for end-stage liver disease
- HBV:
-
Hepatitis B virus
- PT:
-
Prothrombin time
- INR:
-
International normalized ratio
- AST:
-
Aspartate aminotransferase
- WBC:
-
White blood cell counts
- PPG:
-
Portal venous pressure gradient
References
Qi X, Tian Y, Zhang W, Yang Z, Guo X. Covered versus bare stents for transjugular intrahepatic portosystemic shunt: an updated meta-analysis of randomized controlled trials. Therap Adv Gastroenterol. 2017;10:32–41.
Cejna M. Should stent-grafts replace bare stents for primary transjugular intrahepatic portosystemic shunts? Semin Intervent Radiol. 2005;22:287–99.
Yang Z, Han G, Wu Q, Ye X, Jin Z, Yin Z, et al. Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta-analysis. J Gastroenterol Hepatol. 2010;25:1718–25.
Lin ZP, Zhao JB, Chen SL. Analysis of the medium-term curative effect of transjugular intrahepatic portosystemic shunt through jugular vein with covered Viatorr stent. Zhonghua Gan Zang Bing Za Zhi. 2019;27:440–4 (Chinese).
Ferral H, Gomez-Reyes E, Fimmel CJ. Post-transjugular intrahepatic portosystemic shunt follow-up and management in the VIATORR Era. Tech Vasc Interv Radiol. 2016;19:82–8.
Sommer CM, Gockner TL, Stampfl U, Bellemann N, Sauer P, Ganten T, et al. Technical and clinical outcome of transjugular intrahepatic portosystemic stent shunt: bare metal stents (BMS) versus viatorr stent-grafts (VSG). Eur J Radiol. 2012;81:2273–80.
Saad WE, Darwish WM, Davies MG, Waldman DL. Stent-grafts for transjugular intrahepatic portosystemic shunt creation: specialized TIPS stent-graft versus generic stent-graft/bare stent combination. J Vasc Interv Radiol. 2010;21:1512–20.
Wan YM, Li YH, Xu ZY, Wu HM, Wu XN, Xu Y. Comparison of TIPS alone and combined with partial splenic embolization (PSE) for the management of variceal bleeding. Eur Radiol. 2019;29:5032–41.
Wan YM, Li YH, Xu Y, Wu HM, Li YC, Wu XN, et al. Predictors of shunt dysfunction and overall survival in patients with variceal bleeding treated with transjugular portosystemic shunt creation using the fluency stent graft. Acad Radiol. 2018;25:925–34.
Maschke SK, Werncke T, Renne J, Kloeckner R, Marquardt S, Kirstein MM, et al. Transjugular intrahepatic portosystemic shunt (TIPS) dysfunction: quantitative assessment of flow and perfusion changes using 2D-perfusion angiography following shunt revision. Abdom Radiol (NY). 2018;43:2868–75.
Perello MP, Mur JP, Vives MS, Riutort JMM, Artigues AP, Garcia CN, et al. Long-term follow-up of transjugular intrahepatic portosystemic shunt (TIPS) with stent-graft. Diagn Interv Radiol. 2019;25:346–52.
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838–51.
Lv Y, He C, Wang Z, Guo W, Wang J, Bai W, et al. Association of nonmalignant portal vein thrombosis and outcomes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis. Radiology. 2017;285:999–1010.
Takaya H, Uemura M, Fujimura Y, Matsumoto M, Matsuyama T, Kato S, et al. ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the child-turcotte-pugh score and the model for end-stage liver disease score. Hepatol Res. 2012;42:459–72.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the study of liver diseases and the European association for the study of the liver. Hepatology. 2014;60:715–35.
Klinger C, Riecken B, Müller J, Westphal A, Löffler J, Froehlich E, et al. Doppler ultrasound surveillance of TIPS-patency in the era of covered stents - retrospective analysis of a large single-center cohort. Z Gastroenterol. 2018;56:1053–62.
Zhou H, Yao X, Tang SH, Xie M, Feng ZS, Qin JP. Clinical study of transjugular intrahepatic portosystemic shunt with Viatorr stent in 43 cases. Zhonghua Gan Zang Bing Za Zhi. 2021;29:54–9 (Chinese).
Jalan R, Hayes PC, Redhead DN. Shunt insufficiency after TIPSS. Cardiovasc Intervent Radiol. 1998;21:187–8.
Perarnau JM, Le Gouge A, Nicolas C, d’Alteroche L, Borentain P, Saliba F, et al. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial. J Hepatol. 2014;60:962–8.
Qi X, He C, Guo W, Yin Z, Wang J, Wang Z, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with variceal bleeding in liver cirrhosis: outcomes and predictors in a prospective cohort study. Liver Int. 2016;36:667–76.
Qi X, Guo W, He C, Zhang W, Wu F, Yin Z, et al. Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: techniques, indications and results on 51 Chinese patients from a single centre. Liver Int. 2014;34:1164–75.
Bai M, Qi X, Yang Z, Yin Z, Nie Y, Yuan S, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. J Gastroenterol Hepatol. 2011;26:943–51.
Billey C, Billet S, Robic MA, Cognet T, Guillaume M, Vinel JP, et al. A prospective study identifying predictive factors of cardiac decompensation after transjugular intrahepatic portosystemic shunt: the Toulouse algorithm. Hepatology. 2019;70:1928–41.
Busk TM, Bendtsen F, Poulsen JH, Clemmesen JO, Larsen FS, Goetze JP, et al. Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2018;314:G275–86.
Praktiknjo M, Abu-Omar J, Chang J, Thomas D, Jansen C, Kupczyk P, et al. Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. JHEP Rep. 2021;3:100264.
Author information
Authors and Affiliations
Contributions
Hua-Mei Wu, Song-Quan Huang: patient management and follow-up; acquisition of data; drafting manuscript. Yu-Hua Li: patient management and follow-up; acquisition of data. Yue-Meng Wan: study concept and design; statistical analysis and interpretation; draft revison; critical revision of the manuscript for important intellectual content. Ying Xu: study design; administrative, technical, or material support; study coordination and supervision.
Corresponding author
Ethics declarations
Conflicts of interest
All authors including Hua-Mei Wu, Song-Quan Huang, Yue-Meng Wan, Yu-Hua Li, Ying Xu declared no conflict of interest.
Ethical Approval
This study was approved by our institutional ethics committee and conformed to the Helsinki Declaration of 1975, as revised in 2008.
Informed Consent
Individual written informed consents for the TIPS procedures were obtained from all patients or their authorized trustees.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
About this article
Cite this article
Wu, HM., Huang, SQ., Wan, YM. et al. Clinical Outcomes of Transjugular Intrahepatic Portosystemic Shunt (Tips) Creation Using Fluency Versus Viatorr Stent-Grafts: A Single-Centre Retrospective Study. Cardiovasc Intervent Radiol 45, 552–562 (2022). https://doi.org/10.1007/s00270-022-03102-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-022-03102-5
Keywords
- Transjugular intrahepatic portosystemic shunt
- Fluency stent-grafts
- Viatorr stent-grafts
- Shunt patency
- Transplant-free survival